Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

AbbVie Inc. (NYSE: ABBV) and the Chicago Cubs have announced a major multi-year partnership to fight cancer, launching the “Striking Out Cancer” campaign during today’s game against the ...

AbbVie Inc. (NYSE:ABBV) Q1 2025 - Earnings Conference Call April 25, 2025 9:00 PM ETCompany ParticipantsLiz Shea - Senior VP, IRRob Michael - CEOJeff ...

AbbVie Inc. (NYSE:ABBV – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the firm, MarketBeat reports.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock ...

News about AbbVie Inc. Commentary and archival information about AbbVie Inc from The New York Times.

AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on August 7, 2024. This SWOT analysis delves into the company's financials, strategic acquisitions ...

On May 22, 2024, AbbVie, Inc. filed a notice of data breach with the Attorney General of Texas after discovering that confidential information that had been entrusted to the company was subject to ...

AbbVie Inc.'s ability to overcome challenges, strong revenue growth, and reduced risks make investors optimistic. Click for my update on ABBV stock prospects.

AbbVie Inc's robust immunology and oncology portfolio drives its competitive edge. Patent expirations and biosimilar competition present significant challenges. Continued investment in R&D and ...